000			03486nam a22006497a 4500
008			191219s20202020 xxu||||| |||| 00| 0 eng d
022			_a0090-4295
024			_a10.1016/j.urology.2019.11.022 [doi]
024			_aS0090-4295(19)31047-7 [pii]
040			_aOvid MEDLINE(R)
099			_a31786304
245			_aProstate Cancer in Men with Treated Advanced Heart Failure: Should we keep Screening?.
251			_aUrology. 2019 Nov 28
251			_aUrology. 136:46-50, 2020 Feb.
252			_aUrology. 2019 Nov 28
252			_aUrology. 136:46-50, 2020 Feb.
253			_aUrology
260			_c2020
260			_fFY2020
265			_saheadofprint
265			_sppublish
266			_d2019-12-17
501			_aAvailable online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
520			_aCONCLUSION: Our cohort represents the largest known cohort with heart failure treated by LVAD/HT and PCa. Our median age of 59 at PCa diagnosis is considerably younger than the national median of 66.1 Of the 4 individuals diagnosed with PCa, 3 had high grade disease. Given the favorable long-term survival of these patients post-LVAD/HT, age-appropriate treatment for PCa should be continued post-implantation. Copyright (c) 2019. Published by Elsevier Inc.
520			_aMETHODS: Men aged 18-90 with normal pre-transplant PSA who underwent LVAD/HT at MWHC from 2007-2018 were identified. Serum PSA, PCa diagnosis, and treatment were captured and analyzed. Survival was analyzed using Kaplan-Meier curves.
520			_aOBJECTIVES: To evaluate the outcomes of men diagnosed with prostate cancer (PCa) following implanted treatments for advanced heart failure. Given the increasingly favorable 10-year life expectancy, MedStar Washington Hospital Center (MWHC) screens heart transplant (HT) candidates for PCa and other malignancies prior to intervention.
520			_aRESULTS: Data was available for 34 patients. Median age was 53 [IQR=51-58]. Median follow-up was 77mo (95% CI=40-87mo). Six men had post-implant elevated PSA (5.3; SD=8.5) and 4 were diagnosed with PCa. Median age of PCa diagnosis was 59 [IQR=58.5-62). As of 2018, 31 of the 34 patients were living, and none died from PCa. Five-year survival was 96% in those without PCa and 100% in those with PCa (figure 2).
546			_aEnglish
650			_a*Early Detection of Cancer
650			_a*Heart Failure/co [Complications]
650			_a*Heart Failure/su [Surgery]
650			_a*Heart Transplantation
650			_a*Heart-Assist Devices
650			_a*Prostatic Neoplasms/co [Complications]
650			_a*Prostatic Neoplasms/di [Diagnosis]
650			_aAdolescent
650			_aAdult
650			_aAged
650			_aAged, 80 and over
650			_aCohort Studies
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aYoung Adult
651			_aMedStar Georgetown University Hospital Residents
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aUrology
657			_aJournal Article
700			_aKrasnow, Ross E
700			_aMohammed, Selma
700			_aShaw, Nathan
700			_aStamatakis, Lambros
790			_aKowalczyk K, Krasnow RE, Lee HH, Mohammed S, Shaw N, Stamatakis L
856			_uhttps://dx.doi.org/10.1016/j.urology.2019.11.022 _zhttps://dx.doi.org/10.1016/j.urology.2019.11.022
942			_cART _dArticle
999			_c4805 _d4805